Tagrisso (osimertinib) competitors – a quick snapshot
| Category | Competitor drug | Manufacturer | Key distinguishing features | Typical clinical use |
|----------|-----------------|--------------|-----------------------------|---------------------|
| First‑generation EGFR TKIs | Tarceva® (erlotinib) | AstraZeneca | Oral, reversible EGFR inhibitor; first approved for NSCLC | First‑line in EGFR‑mutant NSCLC (before osimertinib became standard) |
| | Iressa® (gefitinib) | Pfizer | Similar to erlotinib; oral, reversible | Same indication as Tarceva; used in first‑line historically |
| Second‑generation EGFR TKIs | Gilotrif® (afatinib) | Pfizer | Irreversible inhibitor of EGFR and HER2 | First‑line or second‑line in EGFR‑mutant NSCLC; used when resistance to first‑gen TKIs develops |
| | Vizimpro® (dacomitinib) | Eli Lilly | Irreversible, pan‑HER family inhibitor | Approved in EU/UK for first‑line EGFR‑mutant NSCLC; gaining traction in the US |
| Third‑generation (next‑generation) | Mobocertinib® (Exkivity) | Eli Lilly | Targets EGFR exon‑20 insertions (a subset of mutations that are resistant to Tagrisso) | Approved for advanced NSCLC with EGFR exon‑20 insertions after platinum therapy |
| | Patritumab‑drug conjugates | Multiple biotech partners | Antibody‑drug conjugates targeting EGFR‑positive tumors | Investigational, not yet FDA‑approved but in clinical trials |
| Combination strategies | Pembrolizumab (Keytruda) + Osimertinib | Merck & AstraZeneca | PD‑1 inhibitor combined with EGFR TKI (under study) | Investigational, exploring synergy in EGFR‑mutant NSCLC |
| | Atezolizumab (Tecentriq) + Osimertinib | Roche & AstraZeneca | PD‑L1 inhibitor combined with EGFR TKI | Investigational |
| Other EGFR‑targeting agents | Poziotinib | Astellas | Potent against a range of EGFR mutations including exon‑20 insertions | Investigational |
| | Lorlatinib (Lorbrena) | Pfizer | Primarily ALK inhibitor but shows activity against some EGFR mutations | Off‑label use in rare cases |
| Generics & Biosimilars | Generic osimertinib | Multiple generic manufacturers (pending approvals) | Same active ingredient as Tagrisso | Cost‑effective alternative once approved |
| | Generic erlotinib, gefitinib, afatinib, dacomitinib | Various | Oral TKIs with similar mechanisms | Alternative first‑line or second‑line options |
How the competition is played out
1. First‑line therapy – In many regions, osimertinib (Tagrisso) is now the preferred first‑line treatment for EGFR‑mutant NSCLC because it’s highly effective against common sensitizing mutations and also covers the T790M resistance mutation. However, afatinib and dacomitinib remain alternatives, especially when osimertinib is not available or patients develop resistance.
2. Resistance and mutation subsets –
- Exon‑20 insertions are notoriously resistant to all first‑ and second‑generation TKIs. Here, mobocertinib and investigational agents (poziotinib, etc.) compete directly with Tagrisso.
- T790M resistance (the most common resistance mechanism to first‑generation TKIs) is what led to the development of osimertinib in the first place; in this niche Tagrisso has the advantage, but generics are becoming available.
3. Cost and accessibility – Generic versions of erlotinib, gefitinib, afatinib, and dacomitinib are already on the market in many countries, and once generic osimertinib is approved, Tagrisso will face direct price competition.
4. Combination strategies – There is active research into combining EGFR TKIs with immune checkpoint inhibitors. While still investigational, these combos could shift the standard of care and alter the competitive landscape.
5. Safety profiles – Each TKI has a slightly different toxicity spectrum (e.g., rash, diarrhea, interstitial lung disease). Some clinicians may prefer a drug with a better tolerability profile for certain patients, influencing prescription patterns.
Bottom line
Tagrisso remains a front‑line, high‑efficacy option for EGFR‑mutant NSCLC, but it competes with a well‑established portfolio of first‑ and second‑generation EGFR TKIs, newer agents targeting difficult mutations, and emerging combination therapies. The competitive dynamics are evolving as generics enter the market, resistance patterns change, and new drugs receive regulatory approval.